What does OODP stand for?

Office of Oncology Drug Products (US FDA)

This definition appears very rarely and is found in the following Acronym Finder categories:

Military and Government
Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Out of Doors Experience Owners, Officers, Directors, Partners, Regents, Trustees, or Executive Personnel Object Oriented Design Heuristic(s) Object Orientated Dynamic Language Object-Oriented Data Model Object-Oriented Design Method (programming) Object Oriented Data Manipulation Language Object-Oriented Database Management System (also seen as ODBMS) Object Oriented Design Pattern Oddhobby Open Directory Project (website)		Ontario Organizational Development Program (est. 1995; Canada) Opolski Osrodek Doradztwa Rolniczego (Polish) Optical-Optical Double Resonance Workshop on Object-Oriented Database Systems Object Oriented Data Technology Old Orlu Divisional Union (UK) Object-Oriented Data Warehouse Object-Oriented Data Warehouse Design Object-Oriented Encapsulation Obligatory Office Equipment

Samples in periodicals archive:

htm FDA Office of Oncology Drug Products http://www.

FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs

At last month's ODAC meeting, Richard Pazdur, director of the FDA's Office of Oncology Drug Products, scolded CTI for submitting an incomplete, single pivotal Phase III trial as the basis for its initial submission of the pixantrone application.

FDA Rejects CTI Lymphoma Drug; Firm to Seek Compassionate Use

Food and Drug Administration's (FDA) Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO(TM) for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

United States : ChemGenex Receives a Complete Response Letter from ...

director of the FDA's Office of Oncology Drug Products, said during a press briefing after the meeting concluded.

FDA panel backs continued but limited ESA use

Richard Pazdur, who heads the FDA's Office of Oncology Drug Products, sabotaged Dendreon's application in order to stake his turf as czar of all cancer-therapy approvals.

FDA sued over Provenge delay; Patients want Dendreon prostate-cancer ...

Food and Drug Administration's (FDA) Office of Oncology Drug Products has issued a complete response letter regarding the new drug application (NDA) for OMAPRO[TM] (omacetaxine mepesuccinate) for the treatment of adults with chronic myeloid leukemia (CML) who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

ChemGenex Receives a Complete Response Letter from the FDA for ...

Approval is not the only pathway to drug access," said Richard Pazdur, director of the FDA's Office of Oncology Drug Products.

ODAC Rejects CTI, ChemGenex Data Claims for Cancer Drugs

Food and Drug Administration's Office of Oncology Drug Products approved more than 50 new indications for the use of oncology and hematology drugs and biologics between July 2005, when the office began reviewing marketing applications, and the end of 2007, according to a new agency study.

United States: FDA Cancer Drug Approval Rate Highlighted In JNCI